Zomedica Corp. (AMEX: ZOM) is 463.75% higher on its value in year-to-date trading and has touched a low of $0.06 and a high of $1.00 in the current 52-week trading range. The ZOM stock was last observed hovering at around $0.93 in the last trading session, with the day’s gains setting it 0.37% off its average median price target of $0.30 for the next 12 months. It is also -333.33% off the consensus price target high of $0.30 offered by 1 analysts, but current levels are -333.33% lower than the price target low of $0.30 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $1.30, the stock is 345.95% and 584.84% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 899.3 million and changing 39.78% at the moment leaves the stock 698.38% off its SMA200. ZOM registered 331.89% gain for a year compared to 6-month gain of 725.40%. The firm has a 50-day simple moving average (SMA 50) of $0.2391 and a 200-day simple moving average (SMA200) of $0.1514.
The stock witnessed a 710.47% loss in the last 1 month and extending the period to 3 months gives it a 1397.70%, and is 196.13% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 30.17% over the week and 18.97% over the month.
Distance from 52-week low is 1970.06% and 30.00% from its 52-week high.
Zomedica Corp. (ZOM) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Zomedica Corp. (ZOM) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Zomedica Corp. is expected to release its quarterly report on 05/18/2021 and quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to shrink by -4.50% this year.
Zomedica Corp. (ZOM) Top Institutional Holders
31 institutions hold shares in Zomedica Corp. (ZOM), with 24.93M shares held by insiders accounting for 4.42% while institutional investors hold 6.62% of the company’s shares. The shares outstanding are 550.54M, and float is at 539.13M with Short Float at 8.02%. Institutions hold 6.33% of the Float.
The top institutional shareholder in the company is Cambridge Investment Research Advisors Inc. with over 12.25 million shares valued at $1.35 million. The investor’s holdings represent 11.34% of the ZOM Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 10.78 million shares valued at $1.19 million to account for 9.97% of the shares outstanding. The other top investors are Millennium Management LLC which holds 2.87 million shares representing 2.66% and valued at over $0.32 million, while Geode Capital Management, LLC holds 1.68% of the shares totaling 1.82 million with a market value of $0.2 million.
Zomedica Corp. (ZOM) Insider Activity
A total of 0 insider transactions have happened at Zomedica Corp. (ZOM) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by POWERS JOHNNY D, the company’s Director. SEC filings show that POWERS JOHNNY D bought 625,000 shares of the company’s common stock on Jul 07 at a price of $0.16 per share for a total of $100000.0. Following the purchase, the insider now owns 0.63 million shares.